Skip to main content
. Author manuscript; available in PMC: 2011 Jun 3.
Published in final edited form as: Oncogene. 2008 Nov 24;28(4):610–618. doi: 10.1038/onc.2008.424

Figure 4.

Figure 4

(a) Cyclin B1 evaluation after gemcitabine in highly sensitive (Panc1 and HS766T) and resistant (MiaPaca2 and L36PL) cell lines after ON 01910.Na treatment. No change in cyclin B1 is observed after gemcitabine treatment in sensitive or resistant cells. (b and c) Small interference RNA (siRNA) of cyclin B1 and Plk1 decreased both mRNA and protein levels in Hs766T and MiaPaca2. Downregulation of polo-like kinase 1 (Plk1) induced increases in cyclin B1 mRNA also in both cell lines, but the effects at the protein level were more evident in HS766T. After assessing the effects of siRNA, cyclin B1 and Plk1 in conjunction with treatment with gemcitabine and ON 01910.Na, it can be concluded that cyclin B1 had no role in determining sensitivity status, nor did have an effect of its own. However, Plk1 downregulation had an effect in HS766T, but not in MiaPaca2, confirming that in the former cell line, cell growth is Plk1-dependent. There was also some additive effect when Plk1 siRNA and ON 01910.Na were given together. Error bars represent s.d.; asterisk indicates Po0.05 (Student's t-test) compared with control.